CXCL1 Decreases Severity Of Multiple Sclerosis-like Disease

Main Category: Multiple Sclerosis
Also Included In: Neurology / Neuroscience
Article Date: 03 Jan 2009 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:5 stars

4.82 (11 votes)

Healthcare Prof:4 and a half stars

4.5 (2 votes)


A group led by Dr. Cedric Raine at Albert Einstein College of Medicine have explored the expression of an immune molecule (CXCL1) that interacts with myelin-producing cells, finding that CXCL1 decreases the severity of disease in a mouse model of multiple sclerosis (MS). They report their data in the January 2009 issue of The American Journal of Pathology.

The autoimmune disease multiple sclerosis (MS) attacks the central nervous system, resulting in demyelination of neurons. Myelin-producing cells in the central nervous system are severely depleted in lesions in patients with MS.

Myelin-producing cells express immune receptors and have been shown to respond to the immune molecule CXCL1, although the role of CXCL1 in MS has not been previously explored. Dr. Raine and colleagues examined the effects of CXCL1 specifically expressed in the nervous system in a mouse model of MS. They observed decreased severity of disease and more prominent remyelination in these mice. CXCL1, therefore, may play a neuroprotective role in CNS autoimmune demyelination.

In future studies, Dr. Raine's group plans to determine how CXCL1 mediates protection in MS. "Exploration of these pathways affords novel therapeutic avenues to enhance the limited remyelination typically seen in MS."

Omari KM, Lutz SE, Santambrogio L, Lira SA, Raine CS
"Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1."
Am J Pathol 2009, 174:164-176

American Journal of Pathology, official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.

Source
Angela Colmone
American Journal of Pathology

Article adapted by Medical News Today from original press release.
Visit our multiple sclerosis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Am J Path. "CXCL1 Decreases Severity Of Multiple Sclerosis-like Disease." Medical News Today. MediLexicon, Intl., 3 Jan. 2009. Web.
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/134299.php>

APA
Am J Path. (2009, January 3). "CXCL1 Decreases Severity Of Multiple Sclerosis-like Disease." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/134299.php.

Please note: If no author information is provided, the source is cited instead.




Multiple Sclerosis

Most Popular Articles



Follow Our Multiple Sclerosis News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Multiple Sclerosis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »